Cargando…
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt
BACKGROUND: Brain metastases occur in up to 75% of patients with advanced melanoma. Most are treated with whole-brain radiotherapy (WBRT), with limited effectiveness. Vandetanib, an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor and rearranged during trans...
Autores principales: | Gupta, Avinash, Roberts, Corran, Tysoe, Finn, Goff, Matthew, Nobes, Jenny, Lester, James, Marshall, Ernie, Corner, Carie, Wolstenholme, Virginia, Kelly, Charles, Wise, Adelyn, Collins, Linda, Love, Sharon, Woodward, Martha, Salisbury, Amanda, Middleton, Mark R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104891/ https://www.ncbi.nlm.nih.gov/pubmed/27711083 http://dx.doi.org/10.1038/bjc.2016.318 |
Ejemplares similares
-
Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012) -
Efficacy and safety of WBRT+EGFR‐TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: An updated meta‐analysis
por: Zhou, Kai, et al.
Publicado: (2021) -
Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021) -
Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017) -
WBRT vs. APBI: an interim report of patient satisfaction and outcomes
por: Bitter, Samantha M., et al.
Publicado: (2016)